119 related articles for article (PubMed ID: 22290434)
1. Phosphorylation of BRN2 modulates its interaction with the Pax3 promoter to control melanocyte migration and proliferation.
Berlin I; Denat L; Steunou AL; Puig I; Champeval D; Colombo S; Roberts K; Bonvin E; Bourgeois Y; Davidson I; Delmas V; Nieto L; Goding CR; Larue L
Mol Cell Biol; 2012 Apr; 32(7):1237-47. PubMed ID: 22290434
[TBL] [Abstract][Full Text] [Related]
2. Histone deacetylase 10 relieves repression on the melanogenic program by maintaining the deacetylation status of repressors.
Lai IL; Lin TP; Yao YL; Lin CY; Hsieh MJ; Yang WM
J Biol Chem; 2010 Mar; 285(10):7187-96. PubMed ID: 20032463
[TBL] [Abstract][Full Text] [Related]
3. Pax3 and hippo signaling coordinate melanocyte gene expression in neural crest.
Manderfield LJ; Engleka KA; Aghajanian H; Gupta M; Yang S; Li L; Baggs JE; Hogenesch JB; Olson EN; Epstein JA
Cell Rep; 2014 Dec; 9(5):1885-1895. PubMed ID: 25466249
[TBL] [Abstract][Full Text] [Related]
4. BRN2 expression increases anoikis resistance in melanoma.
Pierce CJ; Simmons JL; Broit N; Karunarathne D; Ng MF; Boyle GM
Oncogenesis; 2020 Jul; 9(7):64. PubMed ID: 32632141
[TBL] [Abstract][Full Text] [Related]
5. A phosphatidylinositol 3-kinase-Pax3 axis regulates Brn-2 expression in melanoma.
Bonvin E; Falletta P; Shaw H; Delmas V; Goding CR
Mol Cell Biol; 2012 Nov; 32(22):4674-83. PubMed ID: 22988297
[TBL] [Abstract][Full Text] [Related]
6. NFIB Mediates BRN2 Driven Melanoma Cell Migration and Invasion Through Regulation of EZH2 and MITF.
Fane ME; Chhabra Y; Hollingsworth DEJ; Simmons JL; Spoerri L; Oh TG; Chauhan J; Chin T; Harris L; Harvey TJ; Muscat GEO; Goding CR; Sturm RA; Haass NK; Boyle GM; Piper M; Smith AG
EBioMedicine; 2017 Feb; 16():63-75. PubMed ID: 28119061
[TBL] [Abstract][Full Text] [Related]
7. POU domain transcription factor BRN2 is crucial for expression of ASCL1, ND1 and neuroendocrine marker molecules and cell growth in small cell lung cancer.
Ishii J; Sato H; Sakaeda M; Shishido-Hara Y; Hiramatsu C; Kamma H; Shimoyamada H; Fujiwara M; Endo T; Aoki I; Yazawa T
Pathol Int; 2013 Mar; 63(3):158-68. PubMed ID: 23530560
[TBL] [Abstract][Full Text] [Related]
8. BRN2 suppresses apoptosis, reprograms DNA damage repair, and is associated with a high somatic mutation burden in melanoma.
Herbert K; Binet R; Lambert JP; Louphrasitthiphol P; Kalkavan H; Sesma-Sanz L; Robles-Espinoza CD; Sarkar S; Suer E; Andrews S; Chauhan J; Roberts ND; Middleton MR; Gingras AC; Masson JY; Larue L; Falletta P; Goding CR
Genes Dev; 2019 Mar; 33(5-6):310-332. PubMed ID: 30804224
[TBL] [Abstract][Full Text] [Related]
9. BRN2, a POUerful driver of melanoma phenotype switching and metastasis.
Fane ME; Chhabra Y; Smith AG; Sturm RA
Pigment Cell Melanoma Res; 2019 Jan; 32(1):9-24. PubMed ID: 29781575
[TBL] [Abstract][Full Text] [Related]
10. Melanoma Plasticity: Promoter of Metastasis and Resistance to Therapy.
Huang F; Santinon F; Flores González RE; Del Rincón SV
Front Oncol; 2021; 11():756001. PubMed ID: 34604096
[TBL] [Abstract][Full Text] [Related]
11. BRN2 is a non-canonical melanoma tumor-suppressor.
Hamm M; Sohier P; Petit V; Raymond JH; Delmas V; Le Coz M; Gesbert F; Kenny C; Aktary Z; Pouteaux M; Rambow F; Sarasin A; Charoenchon N; Bellacosa A; Sanchez-Del-Campo L; Mosteo L; Lauss M; Meijer D; Steingrimsson E; Jönsson GB; Cornell RA; Davidson I; Goding CR; Larue L
Nat Commun; 2021 Jun; 12(1):3707. PubMed ID: 34140478
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-107 is a novel tumor suppressor targeting POU3F2 in melanoma.
Zhao G; Wei Z; Guo Y
Biol Res; 2020 Mar; 53(1):11. PubMed ID: 32169117
[TBL] [Abstract][Full Text] [Related]
13. CHARGE syndrome modeling using patient-iPSCs reveals defective migration of neural crest cells harboring CHD7 mutations.
Okuno H; Renault Mihara F; Ohta S; Fukuda K; Kurosawa K; Akamatsu W; Sanosaka T; Kohyama J; Hayashi K; Nakajima K; Takahashi T; Wysocka J; Kosaki K; Okano H
Elife; 2017 Nov; 6():. PubMed ID: 29179815
[TBL] [Abstract][Full Text] [Related]
14. Prenatal diagnosis and genetic counseling for Waardenburg syndrome type I and II in Chinese families.
Wang L; Qin L; Li T; Liu H; Ma L; Li W; Wu D; Wang H; Guo Q; Guo L; Liao S
Mol Med Rep; 2018 Jan; 17(1):172-178. PubMed ID: 29115496
[TBL] [Abstract][Full Text] [Related]
15. In the Wnt-er of life: Wnt signalling in melanoma and ageing.
Kaur A; Webster MR; Weeraratna AT
Br J Cancer; 2016 Nov; 115(11):1273-1279. PubMed ID: 27764844
[TBL] [Abstract][Full Text] [Related]
16. In silico studies of the interaction between BRN2 protein and MORE DNA.
do Vale Coelho IE; Arruda DC; Taranto AG
J Mol Model; 2016 Sep; 22(9):228. PubMed ID: 27568376
[TBL] [Abstract][Full Text] [Related]
17. A caveolin-dependent and PI3K/AKT-independent role of PTEN in β-catenin transcriptional activity.
Conde-Perez A; Gros G; Longvert C; Pedersen M; Petit V; Aktary Z; Viros A; Gesbert F; Delmas V; Rambow F; Bastian BC; Campbell AD; Colombo S; Puig I; Bellacosa A; Sansom O; Marais R; Van Kempen LC; Larue L
Nat Commun; 2015 Aug; 6():8093. PubMed ID: 26307673
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms contributing to differential regulation of PAX3 downstream target genes in normal human epidermal melanocytes versus melanoma cells.
Bartlett D; Boyle GM; Ziman M; Medic S
PLoS One; 2015; 10(4):e0124154. PubMed ID: 25880082
[TBL] [Abstract][Full Text] [Related]
19. MITF and PAX3 Play Distinct Roles in Melanoma Cell Migration; Outline of a "Genetic Switch" Theory Involving MITF and PAX3 in Proliferative and Invasive Phenotypes of Melanoma.
Eccles MR; He S; Ahn A; Slobbe LJ; Jeffs AR; Yoon HS; Baguley BC
Front Oncol; 2013 Sep; 3():229. PubMed ID: 24062982
[TBL] [Abstract][Full Text] [Related]
20. Octamer-binding transcription factors: genomics and functions.
Zhao FQ
Front Biosci (Landmark Ed); 2013 Jun; 18(3):1051-71. PubMed ID: 23747866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
